ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
A major study at ENDO 2026 finds global heart disease now peaks at ages 50-54, driven by rising obesity and fastest growth in South Asia.
A study finds sarcopenic obesity, excess belly fat with low muscle, raises death risk by 83% in adults over 50.
Read More
The FDA proposed reclassifying Mycobacterium tuberculosis immunity tests from Class III to Class II devices with new special controls.
Read More
A global analysis of 10,000 knee arthritis patients found knee braces, water therapy, and exercise outperform drug treatments in pain relief and function.
Read More
The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.
Read More
The FDA approved relacorilant (Lifyorli) with nab-paclitaxel for platinum-resistant ovarian cancer, based on improved progression-free survival in a phase 3 trial.
Read More
The FDA approved Sotyktu (deucravacitinib) on March 6, 2026, for adults with active psoriatic arthritis based on positive phase 3 trial results.
Read More
The FDA approved nivolumab with AVD chemotherapy for patients 12+ with untreated Stage III/IV classical Hodgkin lymphoma.
Read More
The FDA approved nivolumab plus AVD for untreated Stage III/IV classical Hodgkin lymphoma in patients aged 12 and older.
Read More
GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.
Read More
Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.
Read More
